Loratadine | Loratidine;SCH 29851;Wyeth Brand of Loratadine;Loratadine Wyeth Brand;Alavert;Clarityn;Claritin | Neurotransmitter | Histamine Receptor

首页 / / / / Loratadine

氯雷他定 /Loratadine {[allProObj[0].p_purity_real_show]}

货号：A188364 同义名： Loratidine;SCH 29851

Loratadine is an inverse agonist of peripheral histamine H1-receptor with IC50 of > 32 μM.

Loratadine 化学结构
CAS号：79794-75-5

Loratadine 3D分子结构
CAS号：79794-75-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Loratadine 纯度/质量文件产品仅供科研

货号：A188364 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

组胺受体亚型比较

产品名称	H1 receptor ↓ ↑	H2 receptor ↓ ↑	H3 receptor ↓ ↑	H4 receptor ↓ ↑	Histamine receptor ↓ ↑	其他靶点	纯度
Hydroxyzine 2HCl							{[allProObj[0].p_purity_real_show]}
Cyclizine	✔						{[allProObj[0].p_purity_real_show]}
Loratadine	+ B(0)AT2, IC50: 4 μM						{[allProObj[0].p_purity_real_show]}
Desloratadine	++ Histamine H1 receptor, IC50: 51 nM						{[allProObj[0].p_purity_real_show]}
Doxylamine succinate	✔						{[allProObj[0].p_purity_real_show]}
Ebastine	✔						{[allProObj[0].p_purity_real_show]}
Tripelennamine HCl	+ H1 receptor, IC50: 30 μM						{[allProObj[0].p_purity_real_show]}
Meclizine dihydrochloride	✔						{[allProObj[0].p_purity_real_show]}
Chlorpheniramine maleate	+++ Histamine H1 receptor, IC50: 12 nM						{[allProObj[0].p_purity_real_show]}
Diphenhydramine HCl	✔						{[allProObj[0].p_purity_real_show]}
Alcaftadine	++++ H1 receptor, pKi: 8.5	++ H2 receptor, pKi: 7.2					{[allProObj[0].p_purity_real_show]}
Fexofenadine HCl	++ Histamine H1 receptor, IC50: 246 nM						{[allProObj[0].p_purity_real_show]}
Bilastine	+++ H1 receptor, Ki: 44.15 nM						{[allProObj[0].p_purity_real_show]}
Pemirolast potassium	✔						{[allProObj[0].p_purity_real_show]}
Bepotastine besilate	+ Histamine H1 receptor, pIC50: 5.7						{[allProObj[0].p_purity_real_show]}
Mizolastine	+++ Histamine H1 receptor, IC50: 47 nM						{[allProObj[0].p_purity_real_show]}
Brompheniramine maleate	✔						{[allProObj[0].p_purity_real_show]}
Carbinoxamine maleate salt	✔						{[allProObj[0].p_purity_real_show]}
Clemastine fumarate	++++ Histamine H1 receptor, IC50: 3 nM						{[allProObj[0].p_purity_real_show]}
Ketotifen fumarate salt	✔						{[allProObj[0].p_purity_real_show]}
Rupatadine Fumarate	++ Histamine H1 receptor, Ki: 102 nM					PAFR	{[allProObj[0].p_purity_real_show]}
Famotidine		✔					{[allProObj[0].p_purity_real_show]}
Roxatidine Acetate HCl		+ Histamine H2 receptor, IC50: 3.2 μM					{[allProObj[0].p_purity_real_show]}
Lafutidine		✔					{[allProObj[0].p_purity_real_show]}
Cimetidine		✔					{[allProObj[0].p_purity_real_show]}
Nizatidine		++++ Histamine H2 receptor, IC50: 0.9 nM				AChE	{[allProObj[0].p_purity_real_show]}
Ranitidine		✔					{[allProObj[0].p_purity_real_show]}
Betahistine			+ Histamine H3 receptor, IC50: 1.9 μM				{[allProObj[0].p_purity_real_show]}
Ciproxifan maleate			+++ Histamine H3 receptor, IC50: 9.2 nM				{[allProObj[0].p_purity_real_show]}
S 38093			++ rat H3 receptor, Ki: 1.44 μM human H3 receptor, Ki: 1.2 μM				{[allProObj[0].p_purity_real_show]}
JNJ-7777120				++++ Histamine H4 receptor, Ki: 4.5 nM			{[allProObj[0].p_purity_real_show]}
Azelastine HCl					✔		{[allProObj[0].p_purity_real_show]}
Epinastine HCl					✔		{[allProObj[0].p_purity_real_show]}
Levodropropizine					✔		{[allProObj[0].p_purity_real_show]}
Cyproheptadine hydrochloride					✔		{[allProObj[0].p_purity_real_show]}
Hesperetin					✔		{[allProObj[0].p_purity_real_show]}
Olopatadine HCl					✔		{[allProObj[0].p_purity_real_show]}
Mianserin hydrochloride					✔		{[allProObj[0].p_purity_real_show]}
Buclizine 2HCl					✔		{[allProObj[0].p_purity_real_show]}
Latrepirdine 2HCl					✔	GluR	{[allProObj[0].p_purity_real_show]}
Cetirizine 2HCl					✔		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Loratadine 生物活性

靶点

H1 receptor

B(0)AT2, IC50:4 μM

描述

Loratadine, a selective inverse agonist of peripheral histamine H1-receptors, is a second-generation antihistaminic drugs suffers limited solubility, poor oral bioavailability (owing to extensive first-pass metabolism), and highly variable oral absorption^[6]. Loratadine exerted its acute and chronic toxicity especially on Ceriodaphnia dubia (LC50: 600 µg/L, EC50: 28.14 µg/L)^[3]. Loratadine at 0.5 and 5 mg/kg did not significantly affect the skeletal system of young rats. At 50 mg/kg, loratadine decreased the femoral length, increased content of calcium and phosphorus in the bone mineral of the vertebra, and tended to improve mechanical properties of the tibial metaphysis^[4]. Loratadine is well tolerated. At dosages of 10 mg daily, commonly reported adverse events were somnolence, fatigue and headache. Sedation occurred less frequently with loratadine than with azatadine, cetirizine, chlorpheniramine, clemastine and mequitazine^[5].

Loratadine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01506791	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft Myers Inc Broadway, Florida, United States, 33901 收起 <<
NCT00816972	Post-nasal Drip ... 展开 >> Seasonal Allergic Rhinitis Rhinorrhea 收起 <<	Phase 2	Completed	-	-
NCT00783211	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-

Loratadine 参考文献

[1]Delpon E, Valenzuela C, et al. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res. 1997 Aug;35(2):341-50.

[2]Genovese A, Patella V, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy. 1997 May;27(5):559-67.

[3]Iesce MR, Lavorgna M, Russo C, Piscitelli C, Passananti M, Temussi F, DellaGreca M, Cermola F, Isidori M. Ecotoxic effects of loratadine and its metabolic and light-induced derivatives. Ecotoxicol Environ Saf. 2019 Apr 15;170:664-672

[4]Folwarczna J, Konarek N, Freier K, Karbowniczek D, Londzin P, Janas A. Effects of loratadine, a histamine H1 receptor antagonist, on the skeletal system of young male rats. Drug Des Devel Ther. 2019 Sep 23;13:3357-3367

[5]Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994 Oct;48(4):617-37

[6]Elkomy MH, El Menshawe SF, Abou-Taleb HA, Elkarmalawy MH. Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization, in vitro/in vivo characterization, and pharmacokinetics in human volunteers. Drug Deliv. 2017 Nov;24(1):781-791

Loratadine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.06mL

2.61mL

1.31mL

26.12mL

5.22mL

2.61mL

Loratadine 技术信息

CAS号	79794-75-5
分子式	C₂₂H₂₃ClN₂O₂
分子量	382.883

别名	Loratidine;SCH 29851;Wyeth Brand of Loratadine;Loratadine Wyeth Brand;Alavert;Clarityn;Claritin
运输	蓝冰

存储条件

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(130.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01506791	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft Myers Inc Broadway, Florida, United States, 33901 收起 <<
NCT00816972	Post-nasal Drip ... 展开 >> Seasonal Allergic Rhinitis Rhinorrhea 收起 <<	Phase 2	Completed	-	-
NCT00783211	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT02646020	Non-small Cell Lung Cancer	Phase 2	Unknown	December 2017	China, Guangdong ... 展开 >> Cancer Center of Sun-Yat Sen University (CCSYSU) GuangZhou, Guangdong, China, 510060 收起 <<
NCT00751166	Urticaria	Phase 4	Terminated(Study could not be ... 展开 >>re-supplied with study medication in a timely manner.) 收起 <<	-	-
NCT00751218	Urticaria	Phase 4	Completed	-	-
NCT00866788	-		Completed	-	-
NCT00779116	Allergies	Phase 4	Completed	-	-
NCT00794378	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00866788	Chronic Idiopathic Urticaria	Phase 2	Completed	-	-
NCT00783146	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00794794	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00780403	-		Completed	-	-
NCT00780403	Allergies	Phase 4	Completed	-	-
NCT02424539	Rhinitis, Allergic, Perennial ... 展开 >>and Seasonal 收起 <<	Phase 4	Completed	-	China, Fujian ... 展开 >> GSK Investigational Site Xiamen, Fujian, China, 361003 China, Guangdong GSK Investigational Site Shenzhen, Guangdong, China, 518038 China, Hunan GSK Investigational Site Changsha, Hunan, China, 410005 GSK Investigational Site Changsha, Hunan, China, 410011 China, Jiangsu GSK Investigational Site Nanjing, Jiangsu, China, 210029 China, Shanxi GSK Investigational Site Taiyuan, Shanxi, China, 030016 China, Zhejiang GSK Investigational Site Wenzhou, Zhejiang, China, 323027 China GSK Investigational Site Beijing, China, 100034 GSK Investigational Site Beijing, China GSK Investigational Site Changsha, China GSK Investigational Site Chongqing, China, 400014 GSK Investigational Site Fuzhou, China, 350025 GSK Investigational Site Hangzhou, China, 310052 GSK Investigational Site Shanghai, China, 200040 GSK Investigational Site Shanghai, China, 200092 GSK Investigational Site Shanghai, China, 200127 收起 <<
NCT00779116	-		Completed	-	-
NCT00895531	Arthroplasty, Replacement, Kne... 展开 >>e 收起 <<	Phase 4	Terminated(Investigator left i... 展开 >>nstitution) 收起 <<	-	United States, Kentucky ... 展开 >> University of Louisville Hospital Louisville, Kentucky, United States, 40202 收起 <<
NCT00895531	-		Terminated(Investigator left i... 展开 >>nstitution) 收起 <<	-	-
NCT00405964	-		Completed	-	-
NCT00406783	Rhinitis, Allergic, Seasonal ... 展开 >> Rhinitis, Allergic, Perennial 收起 <<	Phase 3	Completed	-	-
NCT00536380	-		Completed	-	-
NCT00598611	Chronic Urticaria	Phase 3	Completed	-	Germany ... 展开 >> Allergie-Centrum-Charite Berlin, Germany, 10117 收起 <<
NCT00405964	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00761527	-		Completed	-	-
NCT00536380	Chronic Idiopathic Urticaria	Phase 4	Completed	-	-
NCT00761527	-		Completed	-	-
NCT00779636	Allergic Airway Disease	Phase 4	Completed	-	-
NCT00406783	-		Completed	-	-
NCT01314352	Fed	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC, Ft. Myers, Inc., Ft. Myers, Florida, United States, 33901 收起 <<
NCT01314339	Fasting	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC, Ft. Myers, Inc., Ft. Myers, Florida, United States, 33901 收起 <<
NCT00795522	Urticaria	Phase 4	Completed	-	-
NCT00867191	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00783354	Urticaria Chr... 展开 >>onic Idiopathic Urticaria 收起 <<	Phase 4	Completed	-	-
NCT00600847	Acquired Cold Urticaria	Phase 4	Completed	-	Germany ... 展开 >> Allergie-Centrum-Charité Berlin Berlin, Germany, 10117 收起 <<
NCT01506050	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft Myers Inc Broadway, Florida, United States, 33901 收起 <<
NCT01506037	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft Myers Inc Broadway, Florida, United States, 33901 收起 <<
NCT01444196	Urticaria	Phase 4	Completed	-	Germany ... 展开 >> Department of Dermatology, Venerology and Allergology Berlin, Germany, 10117 收起 <<
NCT02320396	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT01916980	Eczema Dermat... 展开 >>itis Dermal Pruritus 收起 <<	Phase 3	Completed	-	-
NCT01916980	-		Completed	-	-
NCT02771249	Healthy Volunteers	Phase 1	Recruiting	December 31, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov 收起 <<
NCT02478398	Rhinitis, Allergic, Seasonal	Phase 3	Completed	-	-
NCT02320396	-		Completed	-	-
NCT00884325	Atopic Dermatitis ... 展开 >> Pruritus 收起 <<	Phase 4	Completed	-	United States, Kentucky ... 展开 >> DermResearch, PLLC Louisville, Kentucky, United States, 40217 收起 <<
NCT01700192	Rhinitis, Allergic, Perennial ... 展开 >> Rhinitis, Allergic, Nonseasonal 收起 <<	Phase 3	Completed	-	-
NCT01700192	-		Completed	-	-
NCT01390441	Rheumatoid Arthritis	Phase 1	Terminated(The study was termi... 展开 >>nated early by the Sponsor for business reasons.) 收起 <<	-	-
NCT02007434	-		Completed	-	-
NCT02007434	Moderate or Severe Submental F... 展开 >>ullness 收起 <<	Phase 3	Completed	-	United States, Arizona ... 展开 >> Investigational Site Tempe, Arizona, United States, 85283 收起 <<
NCT02545361	Lymphoma	Phase 1 Phase 2	Withdrawn(Program de-prioritiz... 展开 >>ed) 收起 <<	April 2020	-
NCT02495077	Kidney Transplant	Phase 2	Recruiting	September 2020	United States, Alabama ... 展开 >> University of Alabama Recruiting Birmingham, Alabama, United States, 35294 Contact: Elizabeth Harmon 205-996-9632 eharmon@uabmc.edu Principal Investigator: Roslyn B. Mannon, MD United States, California University of California, Los Angeles Recruiting Los Angeles, California, United States, 90024 Contact: Suphamai Bunnapradist 310-794-8516 bunnapradist@mednet.ucla.edu Principal Investigator: Janette Gadzhyan, MD, MS University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Emilio Fernandez 415-353-8380 Emilio.Fernandez@ucsf.edu Principal Investigator: Flavio Vincenti, MD United States, Connecticut Yale University Recruiting New Haven, Connecticut, United States, 06511 Contact: Ricarda Tomlin 203-785-2073 ricarda.tomlin@yale.edu Principal Investigator: Richard Formica Jr., MD United States, Georgia Emory University Recruiting Atlanta, Georgia, United States, 30322 Contact: Elizabeth Ferry 404-712-1816 elizabeth.ferry@emoryhealthcare.org Principal Investigator: Kenneth Newell, MD, PhD United States, Maryland University of Maryland Recruiting Baltimore, Maryland, United States, 21201 Contact: Roberto Ramirez 410-328-0303 rramirez@som.umaryland.edu Contact: Amanda Bartosic (410) 328-0303 abartosic@som.umaryland.edu Principal Investigator: Jonathan S. Bromberg, MD, PhD Johns Hopkins University Not yet recruiting Baltimore, Maryland, United States, 21287 Contact: Mullaney Marlene 410-614-6702 mmulla13@jhmi.edu Contact: Darin Ostrander (410) 614-6702 dostran1@jhmi.edu Principal Investigator: Daniel C. Brennan, MD United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Jennifer Mawby 734-936-4811 jlmawby@med.umich.edu Principal Investigator: Randall Sung, MD United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cusanelli Rebecca 314-362-4109 rcusanel@dom.wustl.edu Principal Investigator: Tarek Alhamad, MD United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Douglas Wilson 212-659-8049 Douglas.Wilson@mountsinai.org Principal Investigator: Madhav Menon, MD Principal Investigator: Peter Heeger, MD United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44106 Contact: Dianna Sendrey 216-444-0486 sendred2@ccf.org Principal Investigator: Emilio Poggio, MD University Hospitals of Cleveland Recruiting Cleveland, Ohio, United States, 44106 Contact: Tracey Lee 216-844-5396 tracey.lee@uhhospitals.org Principal Investigator: Donald Hricik, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53792 Contact: Alyssa Stucke 608-265-1257 stucke@surgery.wisc.edu Principal Investigator: David Foley, MD Canada, Manitoba University of Manitoba Recruiting Winnipeg, Manitoba, Canada, R3A 1R9 Contact: Caroline Slivinski (204) 787-8662 cslivinski@exchange.hsc.mb.ca Principal Investigator: Peter Nickerson, MD Principal Investigator: David Rush, MD Canada, Ontario Toronto General Hospital Recruiting Toronto, Ontario, Canada, M5G 2C4 Contact: Franz Marie Gumabay (416) 340-4800 ext 6806 franzmarie.gumabay@uhn.ca Principal Investigator: Kathryn Tinckam, MD 收起 <<
NCT00884325	-		Completed	-	-
NCT00727727	-		Completed	-	Germany ... 展开 >> Medical Practice for Neurology Dresden, Germany, 01307 Medical Practice for Neurology Wedel, Germany, 22880 收起 <<
NCT00725478	-		Completed	-	-
NCT01507792	Cough Larynge... 展开 >>al Disease Bronchial Disease Iron Deficiency 收起 <<	Not Applicable	Completed	-	Italy ... 展开 >> Respiratory Pathophysiology Clinic, ASO San Giovanni Battista Turin, Italy, 10126 收起 <<
NCT02583594	Progressive Multiple Sclerosis	Phase 1	Active, not recruiting	April 2021	Spain ... 展开 >> Investigational Site Number 724001 Barcelona, Spain, 08035 收起 <<
NCT01390441	-		Terminated(The study was termi... 展开 >>nated early by the Sponsor for business reasons.) 收起 <<	-	-
NCT00562159	-		Completed	-	-
NCT00561717	Seasonal Allergic Rhinitis	Phase 4	Completed	-	Canada, Ontario ... 展开 >> Kingston, Ontario, Canada, K7L 2V7 收起 <<
NCT00550550	Rhinoconjunctivitis ... 展开 >> Rhinitis Conjunctivitis Allergy 收起 <<	Phase 3	Completed	-	-
NCT00721331	Atopic Dermatitis	Phase 1	Completed	-	Germany ... 展开 >> PROINNOVERA GmbH Muenster, Germany 收起 <<
NCT00757562	Chronic Idiopathic Urticaria ... 展开 >> Atopy 收起 <<	Phase 3	Completed	-	-
NCT00481676	Chronic Urticaria	Phase 2	Completed	-	Germany ... 展开 >> Novartis Investigative Site Berlin, Germany Novartis Investigative Site Bonn, Germany Novartis Investigative Site Dresden, Germany Novartis Investigative Site Giessen, Germany Novartis Investigative Site Hamburg, Germany Novartis Investigative Site Hannover, Germany Novartis Investigative Site Koeln, Germany Novartis Investigative Site Leipzig, Germany Novartis Investigative Site Luebeck, Germany Novartis Investigative Site Mainz, Germany Novartis Investigative Site Munich, Germany 收起 <<
NCT00449072	Rhinitis, Allergic, Perennial	Phase 4	Completed	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 收起 <<
NCT00562159	Rhinoconjunctivitis ... 展开 >> Rhinitis Conjunctivitis Allergy 收起 <<	Phase 3	Completed	-	-
NCT01096615	Rhinitis	Phase 3	Completed	-	-
NCT00449072	-		Completed	-	-
NCT01154153	Rhinitis, Allergic, Perennial ... 展开 >>and/or Seasonal 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> Investigational Site Number 840003 Cypress, California, United States, 90630 United States, Georgia Investigational Site Number 840006 Stockbridge, Georgia, United States, 30281 United States, Massachusetts Investigational Site Number 840007 North Dartmouth, Massachusetts, United States, 02747 United States, Minnesota Investigational Site Number 840010 Plymouth, Minnesota, United States, 55441 United States, Nebraska Investigational Site Number 840001 Omaha, Nebraska, United States, 68144 United States, North Carolina Investigational Site Number 840008 Raleigh, North Carolina, United States, 27607 United States, South Carolina Investigational Site Number 840002 Spartanburg, South Carolina, United States, 29307 United States, Texas Investigational Site Number 840005 San Antonio, Texas, United States, 78229 收起 <<
NCT01154153	-		Completed	-	-
NCT00481676	-		Completed	-	-
NCT01007864	Idiopathic Parkinson's Disease	Phase 3	Completed	-	Germany ... 展开 >> Ulm, Baden-Württemberg, Germany, 89081 Wolfach, Baden-Württemberg, Germany, 77709 München, Bayern, Germany, 80804 Berlin-Steglitz, Berlin, Germany, 12163 Marburg, Hessen, Germany, 35043 Göttingen, Niedersachsen, Germany, 37075 Dresden, Sachsen, Germany, 01307 Leipzig, Sachsen, Germany, 04107 Gera, Thüringen, Germany, 07551 Stadtroda, Thüringen, Germany, 07646 Berlin, Germany, 12200 Berlin, Germany, 13353 收起 <<
NCT01413958	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT01519856	-		Completed	-	Germany ... 展开 >> Dr. Erich Scholz Boeblingen, Baden-Wuertemberg, Germany, 71034 收起 <<
NCT00550550	-		Completed	-	-
NCT01413958	-		Completed	-	-
NCT00796211	Plaque Psoriasis	Phase 2	Completed	-	Germany ... 展开 >> ProInnovera Muenster, Germany 收起 <<
NCT03004131	Seasonal Allergic Rhinitis	Phase 4	Completed	-	Canada, Ontario ... 展开 >> Inflamax Research Mississauga, Ontario, Canada, L4W1Ae 收起 <<
NCT00979901	-		Completed	-	-
NCT02517957	Eczema	Phase 2	Unknown	-	-
NCT00972738	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00963469	-		Completed	-	-
NCT00972738	-		Completed	-	-
NCT00960141	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00960141	-		Completed	-	-
NCT01330017	-		Completed	-	-
NCT00963469	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00525382	Urticaria	Phase 3	Completed	-	-
NCT00979901	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00525278	Rhinitis Alle... 展开 >>rgic Seasonal 收起 <<	Phase 3	Completed	-	-
NCT00524836	Rhinitis Alle... 展开 >>rgic Perennial 收起 <<	Phase 3	Completed	-	-
NCT00963599	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00423995	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT02339714	Rhinitis, Allergic, Perennial	Phase 2	Completed	-	China, Beijing ... 展开 >> Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing, Beijing, China, 100053 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences Beijing, Beijing, China, 100700 Mentougou Hospital of TCM Beijing, Beijing, China, 102300 收起 <<
NCT01330017	Rhinitis Seas... 展开 >>onal Rhinitis 收起 <<	Phase 2	Completed	-	-
NCT00946608	Allergy	Phase 1	Completed	-	-
NCT01055756	Allergic Rhinitis	Phase 3	Withdrawn	June 2010	Brazil ... 展开 >> LAL Clínica Pesquisa e Desenvolvimento Ltda Valinhos, São Paulo, Brazil, 13276245 收起 <<
NCT03443843	Rhinitis, Allergic	Phase 4	Completed	-	Canada, Ontario ... 展开 >> Kingston General Hospital Kingston, Ontario, Canada, K7L 2V7 收起 <<
NCT00319995	Rhinitis, Allergic, Seasonal	Phase 3	Completed	-	-
NCT01712009	Bone Pain in Stage I - III Bre... 展开 >>ast Cancer 收起 <<	Phase 2	Completed	-	-
NCT01469234	-		Completed	-	-
NCT01712009	-		Completed	-	-
NCT00963599	-		Completed	-	-
NCT01451996	-		Completed	-	-
NCT01673620	Allergic Rhinitis	Phase 3	Completed	-	-
NCT01673620	-		Completed	-	-
NCT01451996	Healthy	Phase 4	Completed	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT02653339	Rhinitis, Allergic, Perennial	Not Applicable	Unknown	August 2018	China, Beijing ... 展开 >> Peking Union Medical College Hospital traditional Chinese medicine department Not yet recruiting Beijing, Beijing, China, 100730 Contact: Xiaoyang Zhang, Doctor (+86)13910769068 zhangxymz@163.com 收起 <<
NCT02392039	Lymphoma	Early Phase 1	Terminated(Slow Accrual)	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01469234	Rhinitis	Phase 4	Completed	-	-
NCT00776217	Healthy	Not Applicable	Completed	-	-
NCT00762983	-		Completed	-	-
NCT03517930	Clinical Pharmacology	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Frontage Clinical Services Secaucus, New Jersey, United States, 07094 收起 <<
NCT01228630	Perennial Allergic Rhinitis	Phase 3	Completed	-	Brazil ... 展开 >> Lal Clínica Pesquisa E Desenvolvimento Ltda Valinhos, Sao Paulo, Brazil, 13270-245 收起 <<
NCT00776282	Healthy	Not Applicable	Completed	-	-
NCT03517943	Clinical Pharmacology	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Frontage Clinical Services Secaucus, New Jersey, United States, 07094 收起 <<
NCT00837915	Healthy	Not Applicable	Completed	-	Canada, Quebec ... 展开 >> MDS Pharma Services Montreal, Quebec, Canada, H4R2N6 收起 <<
NCT03151720	Healthy	Phase 1	Completed	-	Taiwan ... 展开 >> Tri-Service Genaral Hospital Taipei, Taiwan, 11490 收起 <<
NCT00845546	Healthy	Not Applicable	Completed	-	Canada, Quebec ... 展开 >> MDS Pharma Services St. Laurent, Quebec, Canada, H4R 2N6 收起 <<
NCT00730912	Perennial Allergic Rhinitis	Phase 4	Completed	-	-
NCT02576808	Rhinitis,Allergic	Phase 2	Completed	-	Thailand ... 展开 >> Thammasat University Hospital Khlong Luang,, Pathumthani, Thailand, 12120 收起 <<
NCT02932774	Allergic Rhinitis ... 展开 >> Hay Fever SAR Rhinitis, Allergic, Seasonal 收起 <<	Phase 4	Completed	-	-
NCT02513290	Allergic Rhinitis	Phase 4	Completed	-	-
NCT00963573	Rhinitis	Phase 4	Completed	-	-
NCT03196531	Healthy	Phase 1	Completed	-	China ... 展开 >> Xiangya Hospital Central South University Changsha, China, 410008 收起 <<
NCT03376594	Allergic Rhinitis	Phase 2	Completed	-	Thailand ... 展开 >> Faculty of Medicine Khlong Luang, Pathumthani, Thailand, 12120 收起 <<
NCT02305979	-		Completed	-	United States, North Carolina ... 展开 >> Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States, 27157 收起 <<
NCT03372473	Asthma in Children	Phase 3	Completed	-	-
NCT01311336	Pegfilgrastim-induced Back and... 展开 >> Leg Pain 收起 <<	Phase 2	Unknown	June 2013	United States, Maine ... 展开 >> Cancer Care of Maine Recruiting Brewer, Maine, United States, 04412 Contact: Thomas H Openshaw, MD 207-973-7478 topenshaw@emh.org Principal Investigator: Thomas H Openshaw, MD Sub-Investigator: Andrew Hertler, MD Maine Center for Cancer Medicine Recruiting Scarborough, Maine, United States, 04074 Contact: Matthew Dugan, DO 207-885-7600 duganm@mccm.org Principal Investigator: Matthew Dugan, DO Sub-Investigator: Tracey Weisberg, MD Sub-Investigator: Christian Thomas, MD York Hospital Recruiting York, Maine, United States, 03909 Contact: Jonathan Eneman, MD 207-351-3777 jeneman@yorkhospital.com Principal Investigator: Jonathan Eneman, MD United States, New York CR Wood Cancer Center Recruiting Glens Falls, New York, United States, 12801 Contact: Aqeel Gillani, MD 518-926-6700 aqeelgillani@hotmail.com Principal Investigator: Aqeel Gillani, MD United States, Vermont Mountainview Medical Center Recruiting Berlin, Vermont, United States, 05602 Contact: John Valentine, MD 802-225-5400 john.valentine@cvmc.org Principal Investigator: John Valentine, MD Sub-Investigator: David Ospina, MD Vermont Cancer Center Recruiting Burlington, Vermont, United States, 05405 Contact: Steven M Grunberg, MD 802-656-5457 steven.grunberg@uvm.edu Contact: Karen M Wilson, MEd 802-656-4101 karen.m.wilson@uvm.edu Principal Investigator: Steven M Grunberg, MD Sub-Investigator: Joanna Schwartz, PharmD Vermont Center for Cancer Medicine Recruiting Colchester, Vermont, United States, 05446 Contact: Dennis Sanders, MD 802-655-3400 Dennis.Sanders@vtmednet.org Sub-Investigator: Paul Unger, MD Sub-Investigator: Dennis Sanders, MD Sub-Investigator: Johannes Nunnink, MD 收起 <<
NCT00730912	-		Completed	-	-
NCT02593747	Histamine H1 Antagonists, Non-... 展开 >>Sedating 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> Neu-Ulm, Bayern, Germany, 89231 收起 <<
NCT03640273	Allergic Rhinitis ... 展开 >> Adverse Drug Event Quality of Life 收起 <<	Phase 2	Completed	-	Thailand ... 展开 >> Thammasat University Khlong Luang, Pathumthani, Thailand, 12120 收起 <<

氯雷他定 /Loratadine {[allProObj[0].p_purity_real_show]}

Loratadine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Loratadine 质控信息

Loratadine 生物活性

Loratadine 临床研究

Loratadine 参考文献

Loratadine 实验方案

Loratadine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

氯雷他定 /Loratadine {[allProObj[0].p_purity_real_show]}

Loratadine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Loratadine 质控信息

Loratadine 生物活性

Loratadine 临床研究

Loratadine 参考文献

Loratadine 实验方案

Loratadine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Loratadine 纯度/质量文件产品仅供科研